Amicus Therapeutics Inc (MEX:FOLD)
MXN 208.8 0 (0%) Market Cap: 59.28 Bil Enterprise Value: 63.22 Bil PE Ratio: 0 PB Ratio: 16.63 GF Score: 79/100

Amicus Therapeutics Inc at UBS BioPharma Conference Transcript

Nov 09, 2023 / 06:00PM GMT
Release Date Price: MXN208.8
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at UBS. Thank you so much for joining us here at the UBS Biopharma Conference in Miami. Very happy to have Amicus Therapeutics here with us today for a fireside chat.

Joining us from Amicus is Jeff Castelli, Chief Development Officer. Thanks so much for making the trip to Miami. Maybe just to kick it off, you guys reported earnings yesterday, including first sales in Pompe. So talk a little bit about that.

Jeffrey P. Castelli
Amicus Therapeutics, Inc. - Chief Development Officer

Yes. Thank you, Ellie. Thanks to the UBS team for having us. We're happy to be here. Yes, we just had third quarter earnings yesterday. Very excited to give an update on the launch of Pombiliti and Opfolda in Pompe. As a reminder, we just recently received approval in July in Europe, in August in the U.K. and here at the end of September in the U.S. And I'm really excited by early days of launch. We said that we're well on track to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot